Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026)
Definium Therapeutics (DFTX) reported Other Non-Current Liabilities of $559000.0 for Q1 2026, up 12.7% quarter-over-quarter from $496000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 6 years of Other Non-Current Liabilities data on file, last reported at $559000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $559000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $559000.0 (changed N/A YoY), and the FY2025 annual result was $496000.0, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $559000.0 in Q1 2026 per DFTX's latest filing, from $496000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.9 million in Q2 2022 and troughed at $15000.0 in Q1 2024.
- A 5-year average of $746333.3 and a median of $551000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities sank 38.65% in 2022, then slumped 98.62% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $1.2 million in 2022, then plunged by 97.3% to $32000.0 in 2023, then slumped by 53.12% to $15000.0 in 2024, then jumped by 3206.67% to $496000.0 in 2025, then advanced by 12.7% to $559000.0 in 2026.
- Business Quant data shows DFTX's Other Non-Current Liabilities at $559000.0 in Q1 2026, $496000.0 in Q4 2025, and $519000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 559,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 519,000.00 |
| Jun 30, 2025 | 543,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 992,000.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Dec 31, 2021 | 1.93 Mn |